At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 140 enrolled
Drug / intervention
varenicline +1 moredrug
Likely dose
varenicline 0.5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Menstrual Cycle Effects on Smoking Cessation and Cue Reactivity
In Brief
A Phase 2 clinical trial evaluating varenicline and transdermal nicotine patch for Nicotine Dependence. Completed, enrolled 140 participants across 1 site.
Detailed Summary
This is a brief smoking cessation trial in women, comparing transdermal nicotine patch (TNP) versus varenicline.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNicotine Dependence
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJul 2007
First PostedApr 2008
Primary CompletionDec 2013
TodayJul 2026
First PostedApr 23, 2008
Enrollment StartJul 1, 2007
Primary CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 6.4 yearsPosted 18.2 years ago
Interventions
vareniclinedrug
Day -7 thru -5: 0.5mg QD Day -4 thru -1: 0.5mg BID Day 0 onward: 1.0mg BID Varenicline is taken for a duration of 4 weeks in this study.
transdermal nicotine patchdevice
Weeks 0-3: 21mg patch Transdermal nicotine patch is used for a duration of 3 weeks in this study.